Share

Cardiovascular Systems (CSI) has secured approval for its Diamondback 360 Coronary Orbital Atherectomy System (OAS) Micro Crown from the US Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labor and Welfare (MHLW).

FDA approval allows the device to be used to enable stent delivery in coronary artery disease (CAD) patients who are candidates for percutaneous transluminal coronary angioplasty (PTCA) or stenting related to de-novo, severely calcified coronary artery lesions.

Regulatory approval in Japan recognises the device as a frontline treatment for de-novo severely calcified lesions and to allow access to arteries for percutaneous coronary interventions (PCI). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The atherectomy system is designed to pilot tight, calcific lesions and treat vessels of various sizes, as well as provide continuous blood flow during treatment.

"Patients with severely calcified coronary lesions are some of the most difficult to treat, leading to worse clinical and economic outcomes."

The diamond-coated tip enables instant access through tight, severely calcified lesions and treatment of up to 4mm vessels, while the sanding crown's increased mass facilitates lower rotational speeds.

See Also:

CSI chairman, president and chief executive officer Scott Ward said: "We are committed to continued advancement of CSI’s proven OAS technology focused on severe coronary arterial calcium, which is an underserved problem in vascular medicine.

"Patients with severely calcified coronary lesions are some of the most difficult to treat, leading to worse clinical and economic outcomes.

"The ORBIT II and COAST studies demonstrated that orbital atherectomy technology is safe and effective in treating patients with severely calcified lesions."

The Harmonisation-By-Doing COAST trial was conducted in the US and Japan under the regulations of both governments.